Research Analysts Set Expectations for GANX Q1 Earnings

Gain Therapeutics, Inc. (NASDAQ:GANX) – Research analysts at Roth Capital issued their Q1 2026 earnings per share (EPS) estimates for Gain Therapeutics in a note issued to investors on Sunday, March 30th. Roth Capital analyst B. Pachaiyappan expects that the company will post earnings per share of ($0.27) for the quarter. Roth Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Gain Therapeutics’ current full-year earnings is ($1.00) per share. Roth Capital also issued estimates for Gain Therapeutics’ Q2 2026 earnings at ($0.29) EPS, Q3 2026 earnings at ($0.27) EPS and Q4 2026 earnings at ($0.30) EPS.

Several other equities analysts have also weighed in on GANX. Roth Mkm reiterated a “buy” rating and set a $7.00 price objective on shares of Gain Therapeutics in a report on Tuesday, December 24th. Chardan Capital reissued a “buy” rating and issued a $6.00 price objective on shares of Gain Therapeutics in a research note on Friday, March 28th. Scotiabank initiated coverage on Gain Therapeutics in a research report on Friday, March 7th. They set a “sector outperform” rating and a $12.00 target price on the stock. Finally, HC Wainwright restated a “buy” rating and set a $8.00 price target on shares of Gain Therapeutics in a research note on Monday, March 17th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Gain Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $8.20.

Gain Therapeutics Stock Up 4.4 %

Gain Therapeutics stock opened at $1.89 on Tuesday. The company has a market capitalization of $50.13 million, a PE ratio of -1.72 and a beta of 0.14. Gain Therapeutics has a 12-month low of $0.89 and a 12-month high of $4.04. The firm’s fifty day moving average is $2.20 and its 200 day moving average is $2.07. The company has a quick ratio of 2.99, a current ratio of 2.99 and a debt-to-equity ratio of 0.04.

Gain Therapeutics (NASDAQ:GANX) last released its earnings results on Thursday, March 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.07.

Institutional Investors Weigh In On Gain Therapeutics

Several institutional investors have recently bought and sold shares of GANX. Sprott Inc. bought a new position in Gain Therapeutics during the 4th quarter valued at $30,000. Benedict Financial Advisors Inc. bought a new position in shares of Gain Therapeutics during the fourth quarter valued at about $35,000. Bridgeway Capital Management LLC purchased a new position in Gain Therapeutics during the fourth quarter worth about $65,000. Northern Trust Corp grew its position in Gain Therapeutics by 88.2% in the 4th quarter. Northern Trust Corp now owns 84,586 shares of the company’s stock worth $183,000 after purchasing an additional 39,642 shares in the last quarter. Finally, Marshall Wace LLP purchased a new stake in Gain Therapeutics in the 4th quarter valued at about $198,000. Institutional investors own 11.97% of the company’s stock.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.